Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

By B. Lacas, A. Carmel, C. Landais, Stuart J. Wong, L. Licitra, J. Tobias, B. Burtness, M. Ghi, E. Cohen, C. Grau and 95 more. 2021

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation (2023, background): “For locally advanced (LA) HNSCC patients, primary chemoradiation is an established and frequently used therapeutic option, especially in advanced T stages and with other considerations that make surgery less preferable [2–7].”
Unraveling the Role of Tumor-Infiltrating Immune Cells in Head and Neck Squamous Cell Carcinoma: Implications for Antitumor Immune Responses and Immunotherapy (2025, unknown): “Furthermore, this approach was found to be superior in improving OS by 6.2%, event-free survival (EFS) by 3.7%, and reducing locoregional failure (LRF) by 5.8% at five years, when compared to induction chemotherapy, including taxane-containing triplet regimens [91].”